Anti-CV2 (IgG + IgA)

Optimal Result: 0.1 - 10 Units.

Anti-CV2 antibodies, encompassing both IgG and IgA immunoglobulin classes, target a neuronal protein known as CRMP-5 (Collapsin Response Mediator Protein 5). These antibodies are typically associated with paraneoplastic neurological syndromes (PNS), a group of disorders that arise from the immune system's response to certain cancers. The presence of anti-CV2 antibodies can lead to a variety of neurological manifestations, ranging from cerebellar ataxia, limbic encephalitis, to peripheral neuropathies, and less frequently, myelopathies.

The detection of anti-CV2 antibodies is clinically significant for several reasons. Firstly, they are often indicative of an underlying malignancy, most commonly small cell lung cancer, thymoma, or other neuroendocrine tumors. Therefore, the presence of these antibodies can prompt a search for occult cancer in a patient presenting with neurological symptoms. Secondly, the type and severity of the neurological symptoms associated with anti-CV2 antibodies can vary widely among individuals, reflecting the diverse roles of CRMP-5 in the nervous system.

Additionally, the presence of anti-CV2 antibodies can influence the management and treatment of patients. Treatments may involve immunosuppressive therapies aimed at reducing the autoimmune response, as well as addressing the underlying tumor, if present. Monitoring the levels of these antibodies may provide insight into the response to treatment, although their levels do not always correlate with clinical improvement.

Moreover, the presence of both IgG and IgA anti-CV2 antibodies may have implications for the disease course, as different immunoglobulin classes can be associated with different pathogenic mechanisms and may affect the nervous system in distinct ways. This dual positivity can complicate the clinical picture but also provides a more comprehensive understanding of the patient's immune response.

In summary, anti-CV2 antibodies are important biomarkers for diagnosing and managing paraneoplastic neurological syndromes, guiding the search for underlying malignancies, and informing treatment strategies. Their detection calls for a multidisciplinary approach to patient care, involving oncologists, neurologists, and immunologists to address the complex interplay between the nervous system and cancer-related immune phenomena.


Antoine JC, Honnorat J, Camdessanché JP, Magistris M, Absi L, Mosnier JF, Petiot P, Kopp N, Michel D. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001 Feb;49(2):214-21. doi: 10.1002/1531-8249(20010201)49:2<214::aid-ana41>;2-w. PMID: 11220741.

What does it mean if your Anti-CV2 (IgG + IgA) result is too high?

Anti CV2 antibodies are a group of antibodies that react with a 66 kd brain protein belonging to the family of CRMP proteins. The manifestations associated with anti CV2 antibodies include cerebellar degeneration, uveitis, and peripheral neuropathy, and mixed axonal and demyelinating peripheral neuropathy.

10 000+ happy customers
100% satisfaction
★ ★ ★ ★ ★ customer support

Trust us to examine your lab results, guiding you towards improved health.

Use promo code to save 10% off any plan.

We implement proven measures to keep your data safe.

At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.